Trial Profile
A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial Xeloda Tablets Following Oral Administrations in Adult Patients With Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 May 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Breast cancer; Colorectal cancer
- Focus Pharmacokinetics
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2012 Planned End Date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 15 Aug 2012 Additional trial location (Australia) identified as reported by ClinicalTrials.gov.